These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 24844780)
21. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC Leukemia; 2005 Jul; 19(7):1207-10. PubMed ID: 15858611 [TBL] [Abstract][Full Text] [Related]
22. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952 [TBL] [Abstract][Full Text] [Related]
23. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. Pettitt AR; Jackson R; Carruthers S; Dodd J; Dodd S; Oates M; Johnson GG; Schuh A; Matutes E; Dearden CE; Catovsky D; Radford JA; Bloor A; Follows GA; Devereux S; Kruger A; Blundell J; Agrawal S; Allsup D; Proctor S; Heartin E; Oscier D; Hamblin TJ; Rawstron A; Hillmen P J Clin Oncol; 2012 May; 30(14):1647-55. PubMed ID: 22493413 [TBL] [Abstract][Full Text] [Related]
31. The emerging role of alemtuzumab in chronic lymphocytic leukemia. Nabhan C Clin Lymphoma Myeloma; 2005 Sep; 6(2):115-21. PubMed ID: 16231849 [TBL] [Abstract][Full Text] [Related]
32. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296 [TBL] [Abstract][Full Text] [Related]
33. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251 [TBL] [Abstract][Full Text] [Related]
34. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia. Montillo M; Tedeschi A; Petrizzi VB; Ricci F; Crugnola M; Spriano M; Spedini P; Ilariucci F; Uziel L; Attolico I; Vismara E; De Blasio A; Zaccaria A; Morra E Blood; 2011 Oct; 118(15):4079-85. PubMed ID: 21772050 [TBL] [Abstract][Full Text] [Related]
35. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Demko S; Summers J; Keegan P; Pazdur R Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062 [TBL] [Abstract][Full Text] [Related]